Objective: Endometrioid ovarian carcinoma (EOC) is gynecological malignancy. Prognostic classification of EOC remains challenging, and the role of molecular markers in predicting prognosis is unclear. Cyclin-dependent kinase 1 (CDK1) has been associated with poor prognosis in several malignancies. Here, we investigate the expression of CDK1 in EOC and its relationship with clinicopathological features and prognosis. Methods: We used bioinformatics, reverse transcription-polymerase chain reaction (RT-PCR), and immunohistochemistry to evaluate the expression of CDK1 in EOC. The correlation between CDK1 expression and clinicopathological features was analyzed using the chi-square test. Survival analysis was performed using Kaplan-Meier curves and multivariate Cox analyses. Results: CDK1 was identified as a hub gene associated with EOC using bioinformatics analysis. CDK1 was significantly overexpressed in EOC compared to endometriosis lesions. Positive cytoplasmic CDK1 expression was associated with poor Disease-specific overall survival (HR=4.579, p=0.005) and poor Progression-free survival (HR=4.333, p=0.003). Cytoplasmic CDK1 expression was an independent predictor of Disease-specific overall survival (p = 0.035). Cytoplasmic CDK1 expression and FIGO stage were independent predictors of Progression-free survival (p = 0.013, p = 0.048). Conclusion: Positive cytoplasmic CDK1 expression was associated with advanced FIGO stage and poor prognosis, and was an independent predictor of Disease-specific overall survival and Progression-free survival. Our results suggest that CDK1 expression may be a useful prognostic marker for EOC.

OBJECTIVE: To evaluate the efficacy and safety of up to 24 weeks of triptorelin treatment after conservative surgery for deep infiltrating endometriosis (DIE). DESIGN: Multicentre, prospective, non-interventional. SETTING: 18 tertiary hospitals in China. POPULATION: Premenopausal women aged ≥ 18 years treated with triptorelin 3.75 mg once every 28 days for up to 24 weeks after conservative surgery for DIE METHODS: Endometriosis symptoms were assessed, using a visual analogue scale (0–10 cm) or numerical range (0–10), at baseline (pre-surgery) and routine visits 3, 6, 9, 12, 18 and 24 months after surgery. MAIN OUTCOME MEASURES: Change in symptom intensity over time. RESULTS: A total of 384 women were analysed (mean [SD] age, 33.4 [6.2] years). Scores for all symptoms assessed (pelvic pain, dysmenorrhoea, ovulation pain, dyspareunia, menorrhagia, metrorrhagia and gastrointestinal and urinary symptoms) decreased from baseline over 24 months. Cumulative improvement rates in pelvic pain, dysmenorrhoea, ovulation pain and dyspareunia were 74.4%, 83.6%, 55.1% and 66.9%, respectively. The 24-month cumulative recurrence rate (≥ 1 symptom) was 22.2%. The risk of symptom recurrence was higher in patients with ≥ 2 versus 1 lesion (odds ratio [OR] 2.539; 95% CI: 1.458–4.423; p = 0.001) and patients with moderate (OR 5.733; 95% CI: 1.623–20.248; p = 0.007) or severe (OR 8.259; 95% CI: 2.449–27.851; p = 0.001) pain versus none/mild pain. Triptorelin was well tolerated. CONCLUSIONS: Triptorelin after conservative surgery for DIE improved symptoms over 24 months of follow up. FUNDING: Sponsored by Ipsen